IP Library Patent Application 11960477
Patent Application
App. No. 11/960,477

Islet Cells from Human Embryonic Stem Cells

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/960,477
Abstract

This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine.

Claims (12)

1 . A method of screening a compound for its effect on a primate pancreatic islet cell or a pancreatic islet cell precursor comprising

a) isolating a population of primate pancreatic islet cells or pancreatic islet cell precursors from a cell culture comprising primate pluripotent stem cells (pPS);

b) contacting the isolated population of primate pancreatic islet cells or pancreatic islet cell precursors with the compound; and

c) determining any affect from the compound to the isolated population of primate pancreatic islet cells or pancreatic islet cell precursors from b).

2 . The method of claim one wherein the primate pancreatic islet cells or pancreatic islet cell precursors are human cells.

3 . The method of claim one comprising determining if the compound is toxic to the primate pancreatic islet cells or pancreatic islet cell precursors.

4 . The method of claim one comprising determining if the compound affects insulin expression or insulin secretion.

5 . The method of claim one comprising determining if the compound affects growth of primate pancreatic islet cells or pancreatic islet cell precursors.

6 . A cell culture comprising a) a first population of cells comprising primate pluripotent stem cells (pPS); b) a second population of cells comprising cells that express Sox17, HNF3 and HNF4; and c) Activin A at a concentration suitable to induce expression of Sox17, HNF3 and HNF4 at level that is higher in the second population of cells compared to the first population of cells.

7 . The cell culture of claim 6 , wherein the primate pluripotent stem cells (pPS) are human cells.

8 . The cell culture of claim 6 , further comprising butyrate.

9 . The cell culture of claim 6 , wherein the second population of cells comprises gut endodermal cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2016
From: INOKUMA, MARGARET S.; FISK, GREGORY J.
To: GERON CORPORATION
Reel/Frame 040961/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 031620/0567 →